This newsletter presents you the following key sessions:
1. PODCAST with Dr. Johnson about Durvalumab ± Tremelimumab + Chemotherapy as First-line Treatment for
mNSCLC: Results from the Phase 3 POSEIDON Study
2. Pembrolizumab plus chemotherapy holds promise for recurrent EGFR-mutant non-small cell lung cancer
3. Real-world experience of consolidation durvalumab after concurrent chemoradiotherapy in stage III NSCLC
4. Amivantamab monotherapy demonstrates antitumour activity in METex14 NSCLC
5. Nivolumab plus ipilimumab and chemotherapy efficacious in patients with advanced NSCLC and brain
metastases
